Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2026-05-17 @ 5:57 PM
Study NCT ID:
NCT01100502
Status:
COMPLETED
Last Update Posted:
2021-05-14
First Post:
2010-04-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Sponsor:
Seagen Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Disease, Hodgkin | View |